SIM1811-03

N/A

Report date: 2023/04/10 14:51:42

Base Information

Drug NameSIM1811-03
Drug Alias NameSIM1811-03SIM0235SIM-235
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 1B antagonists
TargetsTumor necrosis factor receptor superfamily member 1B
Therapy Area/IndicationsSolid tumoursLymphoma, T-Cell, CutaneousNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Simcere Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Simcere Biologics Co LtdJiangsu Xiansheng biopharmaceutical Co LtdJiangsu Simcere Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma, T-Cell, Cutaneous
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A